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The CD1d reactive glycolipid, 
 
 
 
-galactosylceramide (
 
 
 
-GalCer), potently activates T cell 
receptor-
 
 
 
 type I invariant NKT cells that secondarily stimulate the proliferation and 
activation of other leukocytes, including NK cells. Here we report a rational approach to 
improving the antitumor activity of 
 
 
 
-GalCer by using delayed interleukin (IL)-21 treatment 
to mature the 
 
 
 
-GalCer–expanded pool of NK cells into highly cytotoxic effector cells. In a 
series of experimental and spontaneous metastases models in mice, we demonstrate far 
superior antitumor activity of the 
 
 
 
-GalCer/IL-21 combination above either agent alone. 
Superior antitumor activity was critically dependent upon the increased perforin-mediated 
cytolytic activity of NK cells. Transfer of 
 
 
 
-GalCer–pulsed dendritic cells (DCs) followed by 
systemic IL-21 caused an even more significant reduction in established (day 8) metastatic 
burden and prolonged survival. In addition, this combination prevented chemical 
carcinogenesis more effectively. Combinations of IL-21 with other NK cell–activating 
cytokines, such as IL-2 and IL-12, were much less effective in the same experimental 
metastases models, and these cytokines did not substitute effectively for IL-21 in 
combination with 
 
 
 
-GalCer. Overall, the data suggest that NK cell antitumor function can 
be enhanced greatly by strategies that are designed to expand and differentiate NK cells via 
DC activation of NKT cells.
 
NK cells are components of the innate immune
system that play a protective role against some
viral infections and tumors (1, 2). These func-
tions are achieved by the ability to recognize
and lyse target cells and the provision of cy-
tokines, such as IFN-
 
 
 
, that control tumor ini-
tiation and metastases (3, 4). We and others have
established that the activation of invariant NKT
(iNKT) cells via the CD1d glycolipid ligand,
 
 
 
-galactosylceramide (
 
 
 
-GalCer), protects the
host from tumor cell metastases in several ex-
perimental mouse models (5–12). iNKT cell
activation by soluble 
 
 
 
-GalCer, leads to rapid
downstream activation of other immune cells,
including NK cells, which express CD69, se-
crete IFN-
 
 
 
, become more cytotoxic, and
proliferate (13). The antimetastatic activity of
soluble 
 
 
 
-GalCer, depends exclusively upon
iNKT cell and NK cell IFN-
 
 
 
 production
(11). Even greater antimetastatic activity of
 
 
 
-GalCer has been achieved by ex vivo pulsing
and transfer of syngeneic DCs with 
 
 
 
-GalCer
(6, 12). Soluble 
 
 
 
-GalCer and 
 
 
 
-GalCer–
pulsed autologous DCs have been examined in
phase I clinical trials in humans who have ad-
vanced cancer, and notably, NK cell activation
has been detected (14, 15). The promising im-
munomodulatory activity of 
 
 
 
-GalCer has
stimulated us to evaluate novel means of further
enhancing host antitumor activity.
Advances have been made in understanding
the cytokines that stimulate NK cell prolifera-
tion; however, much less is known about the
regulation of NK cell differentiation. IL-21 is
related structurally to the lymphoid cytokines,
IL-2, IL-4, and IL-15, and was demonstrated
to be expressed by activated CD4
 
 
 
 T lympho-
cytes (16, 17). The IL-21R is expressed in
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lymphoid tissues and shows homology to the common 
 
 
 
chain of the IL-2 and IL-15 receptors. Like these receptors,
IL-21R forms a complex with 
 
 
 
c and can transduce signals
via the Jak/STAT pathway (18). IL-21 has pleiotropic roles
in the lymphoid lineages, including the promotion of CD8
 
 
 
effector cell function (19) and the inhibition of IgE produc-
tion in B cells (20, 21). Within the NK cell lineage, IL-21
was reported to enhance NK cell maturation from human
multipotent bone marrow progenitors and to activate pe-
ripheral NK cells in the absence of other stimuli (16). This is
in contrast with mouse NK cells, where IL-21 was reported
to have an inhibitory effect on the IL-15–promoted expan-
sion of NK cells, and to have no function in the absence of
activating signals, such as IL-15 or IL-12 (19). After mouse
NK cells are stimulated, IL-21 increases cytotoxicity and
IFN-
 
 
 
 production over that observed for IL-15 alone (19).
The distinct differences between the two species have been
hypothesized to be a result of the immunological naivety of
mouse NK cells as compared with human cells (17). This
late and largely additive function of IL-21 in the mouse NK
cell lineage is compatible with the reported phenotype of IL-
21R–deficient mice, whose in vivo resting NK cell com-
partment is normal (19).
Recently, we (22) and others (23) established that sys-
temic IL-21 alone in vivo promotes NK cell–mediated anti-
metastatic activity. Given the NK cell proliferative effects of
 
 
 
-GalCer and the ability of IL-21 to differentiate further ac-
tivated mouse NK cells, we hypothesized that the combina-
tion of 
 
 
 
-GalCer and IL-21 might display synergistic activi-
ties. Herein, we demonstrate extremely potent innate antitumor
activity and mechanism of the 
 
 
 
-GalCer/IL-21 combination
in a variety of tumor models.
 
RESULTS
 
 
 
-GalCer expands and activates peripheral NK cells
 
Because we previously established that 
 
 
 
-GalCer–mediated
suppression of tumor metastases by activation of iNKT cells
and secondary expansion and activation of NK cells (11), we
reasoned that the ability of IL-21 to differentiate further such
activated NK cells might enable a combined antitumor ac-
tivity of 
 
 
 
-GalCer and IL-21. We first used flow cytometry
of populations of splenocytes harvested from B6 WT mice
receiving 
 
 
 
-GalCer to determine the kinetics of NK cell ac-
tivation and expansion. NK cell numbers were enumerated
and CD3
 
 
 
 NK1.1
 
 
 
 cells were evaluated for CD69 expres-
sion 1, 2, 3, 7, and 10 d after the second of two 1-
 
 
 
g 
 
 
 
-Gal-
Cer inoculations (days 
 
 
 
4 and 0; Fig. 1, Table I). Maximal
numbers of activated NK cells were obtained 2–3 d after the
second inoculation (two- to threefold greater than vehicle
control in spleen and more than 30-fold greater than vehicle
control in liver), whereas the number and activation status of
NK cells began to reduce significantly by 4 d after the final
 
 
 
-GalCer treatment (not depicted and Table I). Expansion
of and CD69 expression on NK cells following the same
 
 
 
-GalCer regime was reduced only slightly in IFN-
 
 
 
 
 
/
 
 
 
mice (not depicted and Table I).
 
Prolonged and elevated NK cell cytotoxicity after 
 
 
 
-GalCer/IL-21 combination
 
On this basis, 3 d after the last 
 
 
 
-GalCer injection was deter-
mined to be a suitable time to administer IL-21. To express
mouse IL-21, we used a hydrodynamics-based gene delivery
technique and a single injection of 20 
 
 
 
g mouse plasmid (p)
IL-21 DNA that previously had been shown to result in high
levels of circulating IL-21 in vivo for up to 5 d after plasmid
administration (22). 
 
 
 
-GalCer–treated mice were injected
with control plasmid open reading frame (pORF) vector or
IL-21 pORF vector 3 d after the second 
 
 
 
-GalCer injection
Figure 1.  -GalCer activates peripheral NK cells. C57BL/6 WT mice 
were treated on days 0 and 4 i.p. with 1  g  -GalCer (200  l). Mice were 
harvested 1, 2, 3, 7, and 10 d after the second  -GalCer injection. Spleen 
cells were examined for NK cell activation as defined by surface CD69 ex-
pression. Naive WT control mice are indicated by the gray line and treated 
mice are indicated by the solid lines. Results are representative of two 
different experiments.
 
Table I.
 
NK cell numbers after 
 
 
 
-GalCer treatment
 
NK cell number (
 
 
 
 10
 
5
 
 
 
 
 
 SD)
Mice Organ Naive
 
Day 3 Day 7
 
B6 WT spleen 26 
 
 
 
 3 69 
 
 
 
 7
 
a
 
24 
 
 
 
 3
liver 1.1 
 
 
 
 0.3 41 
 
 
 
 11
 
a
 
6.1 
 
 
 
 1.0
 
a
 
IFN-
 
 
 
–/–
 
spleen 21 
 
 
 
 4 52 
 
 
 
 6
 
a
 
ND
 
Mice were injected i.p. with 
 
 
 
-GalCer (1 
 
 
 
g) on days 
 
 
 
4 and 0, and spleen and liver 
mononuclear cells were harvested at days 3 and 7. Cells were counted and analyzed 
by flow cytometry to determine the proportion of NK cells as NK1.1
 
 
 
 TCR
 
 
 
 cells.
 
a
 
Significant increase in NK cell number compared to naive state (Mann-Whitney, 
P
 
  
 
 0.05). 
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(where the second injection of 
 
 
 
-GalCer is designated day
0). The cytotoxicity of spleen NK cells toward Yac-1 target
cells was enhanced within 1 d after the second 
 
 
 
-GalCer in-
jection, peaked at 3 d, and diminished rapidly thereafter
(days 4 and 6; Fig. 2 A and not depicted). After a single
pIL-21 treatment on day 3, splenic NK cell cytotoxicity was
elevated by day 6, and some mild level of enhanced cytotox-
icity persisted for 
 
 
 
1 wk (day 11). Most strikingly, the com-
bination of 
 
 
 
-GalCer (days 
 
 
 
4 and 0) and pIL-21 (day 3)
resulted in a very rapid and dramatic increase (20- to 50-
fold) in NK cell cytotoxicity, and these levels of cytotoxic
function were maintained for up to 4 d after pIL-21 treat-
ment (day 7; Fig. 2, A and B). The 
 
 
 
-GalCer/IL-21 combi-
nation demonstrated some level of enhancement of NK cell
cytotoxicity above the control groups almost 2 wk after the
pIL-21 inoculation (day 17; Fig. 2 A).
 
The role of perforin (pfp) and IFN-
 
 
 
 in prolonged NK cell 
cytotoxicity by 
 
 
 
-GalCer/pIL-21
 
 
 
-GalCer/pIL-21 or pIL-21 activation of NK cell–mediated
cytotoxicity was pfp-dependent and reduced in IFN-
 
 
 
 
 
/
 
 
 
mice compared with WT mice (Fig. 3 A). As reported previ-
ously (7), early NK cell–mediated cytotoxicity (day 3) in-
duced by 
 
 
 
-GalCer alone was IFN-
 
 
 
–dependent. We
showed previously that IL-21 markedly enhanced the granule
formation and pfp expression in cultured mature mouse NK
cells, but did not increase NK cell number (22). Consistent
with a lack of effect of IL-21 on NK cell proliferation in vivo
(22), a further expansion of NK1.1
 
 
 
TCR
 
  
 
 
 
 NK cells was
not detected after pIL-21, compared with pORF, treatment
(not depicted). Therefore, we next assessed the expression of
pfp in whole spleen cells harvested from all treated groups at
day 6 (3 d after the pIL-21 treatment; Fig. 3 B). The 
 
 
 
-Gal-
Cer/pIL-21 combination significantly enhanced pfp expres-
sion above that observed for 
 
 
 
-GalCer/pORF or vehicle/
pIL-21 alone. The data strongly suggested that sustained in-
duction of peripheral NK cell cytotoxicity by the 
 
 
 
-GalCer/
pIL-21 combination was due to significant and high levels of
expression of the key cytotoxic molecule, pfp.
The phenotype and cytokine secretion of spleen NK
cells also were assessed in similarly treated mice 1 (not de-
picted) and 3 days after pORF/pIL-21 (Fig. 3 C). Significant
alterations in NK cell maturity were detected. Splenic NK
cells typically express Mac-1 (30% Mac-1lo and 70% Mac-
1hi), and an immature NK cell developmental stage in the
mouse has been defined by Mac-1lo expression (24, 25).
Mice that were treated with  -GalCer displayed a signifi-
cantly greater frequency of Mac-1lo NK cells (Fig. 3 C); this
suggested that although  -GalCer expanded NK cell num-
bers, a large proportion of these were a Mac-1lo phenotype.
Further treatment with the pORF vector did not alter this
distribution; however, in mice receiving pIL-21, a propor-
tion of NK cells was altered significantly as defined by Mac-1hi
expression. The expression level of NKG2D, an activation
receptor that was shown to regulate pfp-mediated cytotoxic-
ity (26), was unchanged by any treatment combination (Fig.
3 C, not depicted). Collectively, these data suggested that
immature NK cells that were generated after  -GalCer in-
jection were matured into highly cytotoxic pfp-expressing
NK cells by IL-21. Although  -GalCer injection was shown
to stimulate early and prolonged (up to 3 d) NK cell IFN- 
production (7, 13), there was no detectable level of NK cell
IFN-  production at 1 (not depicted) and 3 d (Fig. 3 C) after
pORF or pIL-21 treatment.
Figure 2. Prolonged and elevated NK cell pfp-mediated cytotoxicity 
after  -GalCer/IL-21 combination. C57BL/6 WT or gene-targeted mice 
were treated on days  4 and 0 i.p. with 1  g  -GalCer (200  l) or 200  l 
of vehicle, and on day 3 i.v. with 20  g of pORF or pIL-21 DNA plasmid. 
Mice were harvested at various time points, and spleen cells were examined in 
a 4-h 51Cr release assay at several effector/target (E:T) ratios using Yac-1 
target cells. (A) Cytotoxicity of WT spleen cells from treated mice at 25:1 
on various days of harvest and (B) cytotoxicity of WT spleen cells on day 6 
at various E:T ratios. Results were expressed as the mean percentage lysis   
SEM of triplicate samples. N.T., not tested.COMBINED  -GALCER AND IL-21 THERAPY | Smyth et al. 1976
Concurrent assessment of NKT cell and DC populations
in these treated mice revealed that there were no changes in
DC subsets or their activation status after pIL-21 alone (in-
cluding CD40, CD80, CD86, and MHC class II expression),
whereas DC activation by  -GalCer alone was evident 24 h
after the second  -GalCer treatment (unpublished data).
There was no further change to DC subsets or DC activa-
tion at 24 h, 48 h, 4 d, or 7 d after the pIL-21 treatment that
followed  -GalCer. In addition, iNKT cell number and ac-
tivation was not further enhanced above  -GalCer treat-
ment by pIL-21 (unpublished data).
 -GalCer/IL-21 combination suppresses tumor 
metastases and prolongs survival by pfp- and 
IFN- –dependent mechanisms.
Given the potent antimetastatic activity of early  -GalCer
treatment alone, we examined the  -GalCer/pIL-21 combi-
nation in two (early and late) different treatment regimes
against B16F10 experimental metastases. Mice that received
 -GalCer (days 0 and 4) alone demonstrated a significant re-
duction in B16F10 lung metastases compared with vehicle/
pORF control–treated mice (Fig. 4 A). By contrast, when
 -GalCer treatment was delayed (days 4 and 8), this therapy
only caused a minor reduction in control lung metastases
(Fig. 4 B). Mice receiving pIL-21 alone on days 7 (early) or
11 (late) demonstrated similar numbers of metastases as con-
trol-treated mice (Fig. 4, A and B). The early  -GalCer
combination eliminated B16F10 lung metastases almost
completely (Fig. 4 A), and even late treatment enabled a
 60% reduction of established (day 8) metastases (Fig. 4 B).
Suppression of B16F10 tumor metastases by the  -GalCer
combination correlated with a significant increase in the
mean survival time of these cohorts of mice (Fig. 4, C and
D). The  -GalCer/pIL-21 combination was only more ef-
fective than  -GalCer alone when IL-21 was administered
on day 7 (3 d after the second  -GalCer treatment; Fig. 4 E).
Although  -GalCer alone has limited activity against estab-
lished subcutaneous B16F10, the  -GalCer/pIL-21 combi-
nation suppressed B16F10 tumor growth almost completely
(Fig. S1, A and B, available at http://www.jem.org/cgi/
content/full/jem.20042280/DC1).
We (11) and others (7) showed that the antimetastatic
activity of  -GalCer was completely IFN- –dependent,
whereas pIL-21 suppressed B16F10 lung metastases by a
pfp-dependent mechanism (22). Therefore, the effectiveness
of the late  -GalCer/pIL-21 combination was examined in
Figure 3. The role of pfp and IFN-  in prolonged NK cell cytotoxicity 
by  -GalCer/pIL-21. C57BL/6 WT or gene-targeted mice were treated on 
days  4 and day 0 i.p. with 1  g  -GalCer (200  l) or 200  l of vehicle, 
and on day 3 i.v. with 20  g of pORF or pIL-21 DNA plasmid. Mice were 
harvested at various time points, and spleen cells examined in a 4-h 51Cr 
release assay at several effector/target (E:T) ratios using Yac-1 target cells. 
(A) Cytotoxicity at 25:1 on days 3, 6, and 10 for spleen cells from WT versus 
gene-targeted mice. Results were expressed as the mean percentage
lysis   SEM of triplicate samples. N.T., not tested. (B) Western analysis of 
spleen cells harvested from vehicle/pORF-, vehicle/pIL-21–,  -GalCer/
pORF–, and  -GalCer/pIL-21–treated WT mice 3 d after the pORF/pIL-21 
injection (day 6 above). Immunoblots were probed with mAb to pfp (67 kD) 
or  -tubulin (50 kD) and visualized by enhanced chemiluminescence. 
(C)  -GalCer–treated mice were injected with control pORF or pIL-21 
vector on day 3 after the second  -GalCer injection. Mice were harvested 
3 d after the pORF vector injection, and spleen cells were examined for NK 
cell surface phenotype and intracellular IFN-  levels. As internal control, 
naive B6 mice were injected with poly I:C (200  g), and spleen cells were 
harvested 3 h later and subjected to intracellular IFN-  staining. Results 
are representative of two different experiments.JEM VOL. 201, June 20, 2005 1977
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several gene-targeted mice or WT mice depleted of NK
cells (Fig. 5 A). The combination therapy was completely
ineffective in RAG-1 /  mice (that lack iNKT cells) or
WT mice depleted of NK cells. The combination also was
without synergistic activity in mice that were deficient for
pfp, IFN- , or IL-12, whereas no activity was retained in
mice that were deficient in pfp and IFN-  (Fig. 5 A).
Host IL-18 activity was not required for the synergistic ac-
tivity of  -GalCer/pIL-21. Thus, a combination of IFN- –
and pfp-dependent mechanisms mediates the antimetastatic
function of  -GalCer and pIL-21. In a similar fashion in
BALB/c WT mice, the combination of  -GalCer and pIL-
21 synergistically suppressed Renca lung metastases, and
suppression was critically dependent upon pfp and IFN- 
(Fig. 5 B).
 -GalCer/IL-21 combination suppresses spontaneous 
tumor metastases
To examine the effects of  -GalCer/pIL-21 in a model of
spontaneous tumor metastases, the combination was assessed
in the orthotopic 4T1 mammary tumor model in BALB/c
WT mice. Mice were inoculated in the mammary gland and
8 d later the primary tumor ( 10 mm2) was resected, leaving
micrometastases several organs, including lung, liver, lymph
node, and bone. Mice received  -GalCer (1  g) on days 10
and 14 and pIL-21 (20  g) on day 17 after tumor inocula-
Figure 4.  -GalCer/IL-21 combination suppresses tumor metastases 
and prolongs survival. Groups of five C57BL/6 WT mice were injected i.v. 
with 5   105 B16F10 tumor cells. Mice were treated: (A and C) on days 0 
(the day of tumor inoculation) and 4 i.p. with 1  g  -GalCer (200  l) or 
200  l of vehicle and on day 7 i.v. with 20  g of pORF or pIL-21 DNA 
plasmid; (B and D) on days 4 and 8 i.p. with 1  g  -GalCer (200  l) or 
200  l of vehicle and on day 11 i.v. with 20  g of pORF or pIL-21 DNA 
plasmid; and (E) on days 0 and 4 i.p. with 1  g  -GalCer (200  l) or 
200  l of vehicle and on days 4, 7, or 10 i.v. with 20  g of pIL-21 DNA or 
pORF (day 7) plasmid as indicated. In some experiments (A, B, and E), 14 d 
after tumor inoculation the lungs of the mice were harvested, and tumor 
colonies were counted and recorded as the mean number of colonies   
SEM. Asterisks indicate the groups in which combined  -GalCer/pIL-21 
treatment significantly reduced the number of lung metastases compared 
with all other groups (Kruskal-Wallis: *P   0.05). In other experiments 
(C and D), the survival of the mice was monitored and recorded as the 
mean survival time (days)   SEM. Asterisks indicate the groups in which 
combined  -GalCer/pIL-21 treatment significantly increased survival 
compared with all other groups (Kruskal-Wallis: *P   0.05). Results are 
representative of three experiments.COMBINED  -GALCER AND IL-21 THERAPY | Smyth et al. 1978
tion and were killed on day 25 and lung and liver metastases
quantitated, or were left to monitor survival (Fig. 6, A and
B). The combination of  -GalCer/pIL-21 had a dramatic
effect on lung and liver metastases (Fig. 6, A and B); this sup-
pression resulted in a significant prolongation in lifespan of
this treated group (Fig. 6 C). By contrast,  -GalCer or pIL-
21 treatment alone basically was without effect.
 -GalCer/DC/IL-21 combination mediates extremely potent 
suppression of tumor metastases
Because it was shown previously that  -GalCer was far more
effective in suppressing tumor metastases when administered
pulsed on DCs (6), we next assessed the efficacy of a combi-
nation of  -GalCer/DC and pIL-21 in the B16F10 model.
In concert with the published data,  -GalCer–pulsed BM-
DCs (GM-CSF and IL-4 cultured) were effective in sup-
pressing B16F10 lung metastases, particularly when treat-
ment commenced early (day 4; Fig. 7 A). Some discernable
reduction in lung metastases was observed, even when
 -GalCer–pulsed DCs were transferred 8 d after tumor in-
oculation (day 8; Fig. 7 B). As shown previously, pIL-21
alone (days 7 or 11) had little or no effect on B16F10 lung
metastases (Fig. 7, A and B). By contrast, the combination of
 -GalCer/DC and pIL-21 reduced B16F10 lung metastases
Figure 5.  -GalCer/IL-21 combination suppresses tumor metastases 
by pfp and IFN- -dependent mechanisms. Groups of (A) five C57BL/6 
WT and C57BL/6 gene-targeted mice were injected i.v. with 5   105 B16F10 
tumor cells and (B) five BALB/c WT and BALB/c gene-targeted mice were 
injected with 2.5   105 Renca tumor cells. Some groups of mice were de-
pleted of NK cells by treatment with rabbit anti-asGM1 antibody on days 
 1, 0 (the day of tumor inoculation), and 7. Mice were treated: (A) on days 
4 and 8 i.p. with 1  g  -GalCer (200  l) or 200  l of vehicle and on day 11 
i.v. with 20  g of pORF or pIL21 DNA plasmid; and (B) on days 0 (the day 
of tumor inoculation) and 4 i.p. with 1  g  -GalCer (200  l) or 200  l of 
vehicle and on day 7 i.v. with 20  g of pORF or pIL21 DNA plasmid. In both 
experiments (A and B), 14 d after tumor inoculation the lungs of these mice 
were harvested, and tumor colonies were counted and recorded as the 
mean number of colonies   SEM. Asterisks indicate the groups in which 
combined  -GalCer/pIL-21 treatment did not reduce lung metastases 
significantly compared with WT mice (Kruskal-Wallis: *P   0.05).JEM VOL. 201, June 20, 2005 1979
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dramatically, even when treatment commenced as late as day
8 after tumor inoculation (Fig. 7 B). The striking reduction
in B16F10 lung metastases correlated tightly with a greatly
enhanced survival of mice that received  -GalCer/DC and
pIL-21 combination (Fig. 7, C and D). Recently, we ob-
tained access to mouse recombinant IL-21. To illustrate that
recombinant mouse IL-21 protein could be as effective as
pIL-21 and that the vector DNA sequence itself was not
contributing to the antitumor activity, we examined the ef-
fectiveness of late  -GalCer/DC (day 8) and IL-21 (50  g
on days 11, 12, and 13) treatment on B16F10 lung me-
tastases (Fig. 7 E). Clearly, similar results were obtained with
recombinant mIL-21, which indicates that it was a practical
strategy to proliferate and mature NK cells sequentially using
a surrogate iNKT cell ligand and IL-21 cytokine.
 -GalCer/DC/IL-21 combination suppresses tumor initiation
To assess the ability of the combination of  -GalCer/DC and
pIL-21 to prevent primary tumor initiation, we evaluated
methylcholanthrene (MCA)-induced sarcoma formation. We
had demonstrated previously that early treatment with soluble
 -GalCer alone could prevent a proportion of mice from
succumbing to MCA-induced sarcoma (27). Consistent with
those previous findings, we observed that three early  -Gal-
Cer/DC/pORF treatments given every 2 wk could prevent
sarcoma formation in approximately half of the cohort of
MCA-inoculated mice (Fig. 8). Strikingly, similar early treat-
ment with  -GalCer/DC/pIL-21 prevented tumor forma-
tion in all mice. Enhancement in protection also was ob-
served when treatment commenced at day 70 (at a time when
control mice were first developing palpable sarcomas); 50% of
the mice that received  -GalCer/DC/pIL-21 were protected
from sarcoma (Fig. 8). Delayed  -GalCer/DC/pORF treat-
ment was comparatively ineffective as was early or late treat-
ment with vehicle-loaded DCs and IL-21 (Fig. 8). These re-
sults illustrated that the synergistic activity of  -GalCer/IL-21
was not limited to suppression of experimental metastases, al-
though clearly this is a model system in which host NK cells
are important natural effectors.
IL-2 and IL-12 do not mimic the activity of  -GalCer 
or IL-21 in combination
The success of the  -GalCer/pIL-21 combination raised
questions as to whether a similar efficacy could be obtained
by expanding NK cells by a different means, or further acti-
vating NK cells by cytokines other than IL-21. Having pre-
viously established the activity of single early IL-2 and IL-12
cytokine therapy against Renca lung metastases (28), we
Figure 6.  -GalCer/IL-21 combination suppresses spontaneous 
tumor metastases. Groups of five BALB/c WT mice were injected into the 
mammary gland with 2.5   104 4T1 tumor cells. On day 8 primary tumors 
were resected surgically. Mice were treated on days 10 and 14 i.p. with 1 
 g  -GalCer (200  l) or 200  l of vehicle and on day 17 i.v. with 20  g of 
pORF or pIL21 DNA plasmid. Some groups of mice were killed at day 25 
and (A) liver and (B) lung metastases were quantitated as described in
Materials and methods. Tumor metastases were counted and recorded as 
the mean number of metastases   SEM. Asterisks indicate the groups in 
which combined  -GalCer/pIL-21 treatment reduced metastases signifi-
cantly compared with WT mice (Kruskal-Wallis: *P   0.05). (C) Other iden-
tical treatment groups were monitored for survival, and data were re-
corded as mean survival time (days)   SEM. Asterisks indicate the groups in 
which combined  -GalCer/pIL-21 treatment significantly increased survival 
compared with all other groups (Kruskal-Wallis: *P   0.05). Results are 
representative of two experiments.COMBINED  -GALCER AND IL-21 THERAPY | Smyth et al. 1980
used this tumor model to examine whether these cytokines
might synergize with IL-21 against more established me-
tastases. Using an analogous treatment protocol, BALB/c
WT mice received 5 d of sequential IL-2 or IL-12 treatment
before commencing IL-21 on the last day of IL-2 or IL-12
treatment. In contrast to  -GalCer–pulsed DCs, IL-12 did
not significantly synergize with IL-21 to reduce B16F10 me-
tastases (Fig. 9 A). IL-2 had only a minor significant effect in
combination with IL-21, which suggested that simply ex-
panding NK cells before their differentiation with IL-21 may
not be sufficient (Fig. 9 A). The same cytokines also were
examined for their ability to activate NK cells 2 d after
iNKT cell activation by  -GalCer/DC. IL-2 and IL-12
were unable to reduce Renca lung metastases further after
 -GalCer/DC treatment, but the activity of IL-21 was supe-
rior in combination with  -GalCer (Fig. 9 B).
DISCUSSION
iNKT cells are particularly potent immunoregulatory T cells
that can be activated after interaction with DCs to stimulate
Figure 7.  -GalCer/DC/IL-21 combination mediates extremely potent 
suppression of tumor metastases. Groups of five C57BL/6 WT mice were 
injected i.v. with 5   105 B16F10 tumor cells. Mice were treated: (A and C) 
on days 0 (the day of tumor inoculation) and 4 i.v. with 5   105  -GalCer–
pulsed DCs ( ) or vehicle-pulsed DCs (–) and on day 7 i.v. with 20  g of 
pORF or pIL21 DNA plasmid; and (B and D) on days 4 and 8 i.v. with 5   105 
 -GalCer–pulsed DCs ( ) or vehicle-pulsed DCs ( ) and on day 11 i.v. 
with 20  g of pORF or pIL21 DNA plasmid; and (E) on days 4 and 8 i.v. 
with 5   105  -GalCer–pulsed DCs ( ) or vehicle-pulsed DCs ( ) and on 
days 11, 12, and 13 with 50  g of recombinant mouse IL21 or PBS. In 
some experiments (A, B, and E), 14 d after tumor inoculation the lungs of 
these mice were harvested, and tumor colonies were counted and recorded 
as the mean number of colonies   SEM. Asterisks indicate the groups in 
which combined  -GalCer/DC/IL-21 treatment significantly reduced the 
number of lung metastases compared with all other groups (Kruskal-Wallis: 
*P   0.05). In other experiments (C and D) the survival of these mice was 
monitored and recorded as the mean survival time (d)   SEM. Asterisks 
indicate the groups in which combined  -GalCer/DC/pIL-21 treatment 
significantly increased survival compared with all other groups (Kruskal-
Wallis: *P   0.05). Results are representative of two experiments.JEM VOL. 201, June 20, 2005 1981
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innate and adaptive tumor immunity. Herein, we have
shown that a DC–iNKT cell interaction prompted by the
CD1d-reactive ligand,  -GalCer, can create a pool of pre-
stimulated NK cells that responds strongly to systemic IL-21
treatment. In a series of tumor models in mice, we demon-
strate the far superior antitumor activity of the  -GalCer/IL-21
combination above either agent alone. Transfer of  -Gal-
Cer–pulsed DCs followed by systemic IL-21 caused a partic-
ularly significant reduction in established (day 8) metastatic
burden and prolonged survival. The combination also was
effective in the early treatment of subcutaneous disease and
in preventing MCA-induced sarcoma. Combinations of IL-
21 with other NK cell–activating cytokines, such as IL-2 and
IL-12, were not effective in the same experimental models,
and these cytokines did not substitute effectively for IL-21 in
combination with  -GalCer. However, the production of
both of these cytokines by DCs was an important compo-
nent in the effectiveness of the  -GalCer/IL-21 combina-
tion. The superior antitumor activity of  -GalCer/IL-21
also was critically dependent upon increased and sustained
pfp-mediated cytotoxicity by NK cells and host IFN-  ac-
tivity. Overall, the data suggest that NK cell antitumor func-
tion can be enhanced greatly by strategies that are designed
to expand and differentiate NK cells via DC activation of
NKT cells.
In two different experimental tumor metastases models,
the combination of  -GalCer and IL-21 required pfp- and
IFN- –dependent mechanisms for optimal antitumor activ-
ity. IL-21 alone previously was shown to differentiate NK
cells terminally and greatly enhance their pfp-mediated cy-
tolytic activity and cytokine secretion (IFN-  and IL-10;
reference 22). In several different experimental models, the
in vivo antitumor activity of IL-21 also seemed to be strictly
dependent upon pfp-mediated cytotoxicity (22, 29). Herein,
we have shown enhanced pfp expression and sustained NK
cell pfp-dependent cytotoxicity when IL-21 treatment fol-
lowed  -GalCer priming. More NK cells also were mature
as defined by Mac-1hi expression after the addition of pIL-
21, whereas NK cells from pORF-treated mice contained a
greater proportion of Mac-1lo NK cells that have been
shown to be immature and display lower cytotoxic activity
compared with Mac-1hi NK cells (24). Significant NK cell
IFN-  production was not detected after the  -GalCer/IL-
21 combination. Therefore, we contend that the synergistic
antitumor activity of the  -GalCer/IL-21 combination is
Figure 8.  -GalCer/DC/IL-21 combination suppresses MCA initiation 
of sarcoma. Groups of 10 C57BL/6 WT mice were injected s.c. into the 
hind flank with 400  g MCA as described (27). Mice were treated early on 
days 0 (the day of MCA inoculation), 14, and 28 i.v. with 5   105  -GalCer–
pulsed DCs ( ) or vehicle-pulsed DCs ( ) and days 3, 17, and 31 i.v. with 
20  g of pORF or pIL21 DNA plasmid. Alternatively, mice were treated late 
on days 70, 84, and 98 i.v. with 5   105  -GalCer–pulsed DCs ( ) or vehi-
cle-pulsed DCs ( ) and on days 73, 87, and 101 i.v. with 20  g of pORF or 
pIL21 DNA plasmid. Palpable sarcomas ( 15 mm2) were recorded and 
tumor-free mice were monitored for 250 d.
Figure 9. IL-2 and IL-12 do not mimic the activity of  -GalCer or 
IL-21 in combination. All groups of five BALB/c WT mice were injected 
with 2.5   105 Renca tumor cells. (A) Mice were treated with: (i) 5   105 
 -GalCer–pulsed DCs or vehicle-pulsed DCs i.v. on day 8; (ii) IL-2 (50,000 
IU) i.p. on days 6, 7, 8, 9, and 10; or (iii) IL-12 (500 ng) i.p. on days 6, 7, 8, 9, 
and 10. These groups of mice received 50  g IL-21 or PBS i.p. on days 11, 
12, and 13. (B) Mice were treated with 5   105  -GalCer–pulsed DCs or 
vehicle-pulsed DCs i.v. on day 8. These groups of mice received 50  g IL-21 
or PBS i.p. on days 11, 12, and 13; IL-2 (50,000 IU) i.p. on days 10, 11, 12, 
13, and 14; or IL-12 (500 ng) i.p. on days 10, 11, 12, 13, and 14. In both 
experiments (A and B), 14 d after tumor inoculation, the lungs of the mice 
were harvested, and tumor colonies were counted and recorded as the 
mean number of colonies   SEM. Asterisks indicate the groups in which 
combined  -GalCer/DC/IL-21 treatment significantly reduced lung me-
tastases compared with all other combinations (Kruskal-Wallis: *P   0.05).COMBINED  -GALCER AND IL-21 THERAPY | Smyth et al. 1982
explained largely by the sustained increase in pfp-dependent
cytotoxicity mediated by NK cells that have been expanded
in number after  -GalCer activation of iNKT cells and fully
matured by IL-21. The role that IFN-  plays in the antitu-
mor activity of the  -GalCer/IL-21 combination is less ob-
vious. Clearly,  -GalCer alone demonstrates pfp-indepen-
dent antitumor activity that requires IFN-  secretion by NK
cells and iNKT cells, and the enhanced cytotoxicity of NK
cells after  -GalCer treatment is IFN- -dependent (7, 11).
The retention of considerable antitumor activity of the
 -GalCer/IL-21 combination in IFN-  /  mice was con-
sistent with the ability of  -GalCer to expand NK cell num-
bers in IFN- –deficient mice to a large extent (Table I). It
remains possible that early IFN-  secretion by iNKT cells or
NK cells after  -GalCer may be required for additional
downstream effects on NK cells or other cellular populations
that may respond to IL-21.
Although soluble  -GalCer and DC– -GalCer were re-
ported to act primarily via DC IL-2 and IL-12 production
(6, 11, 30), these cytokines could not substitute for  -Gal-
Cer when administered systemically before IL-21 injection.
In part, this may be because  -GalCer additionally elicits IL-3,
GM-CSF, and TNF from mouse and human NKT cells
that may enable the peripheral mobilization of myeloid pro-
genitors (15, 31, 32), and greater NK cell proliferation and
NK cell cytotoxicity (33–35). Preliminary experiments sug-
gest some role for DC IL-2 and IL-12 in the synergistic ac-
tivity of the  -GalCer/DC/IL-21 combination (unpub-
lished data). We were unable to test the importance of IL-15
produced by DCs in the synergistic activity of  -GalCer/IL-
21; however, our previous studies indicated that IL-15 and
IL-21 together promote the terminal differentiation of NK
cells (22), and others recently showed that DC IL-15 is not
always the most important regulator of NK cell activity (36,
37). Nevertheless, a possible role of DC IL-15 in  -GalCer/
IL-21 synergy remains to be tested formally.
This study raises the possibility that IL-21 might be used
successfully with other biological response modifiers to stim-
ulate tumor immunity. Fms-like tyrosine kinase 3 ligand
(Flt3L) administration inhibits experimental tumor me-
tastases in an NK cell–dependent manner (38), and Flt3L in
combination with IL-2 (39), IL-12, or CD40L (40) demon-
strated some enhanced antitumor activities. However, Flt3L
increases the relative number of functional NK cells in the
spleen and blood of mice in vivo (38, 41, 42), and dose- and
time-dependent increases in NK cell number up to  30-
fold were reported in some organs (42). Therefore, we are
examining the combined antitumor activity of Flt3L and IL-
21. The capacity of IL-21 to enhance pfp-mediated cytotox-
icity may be realized fully in stimulating the antibody-
dependent cellular cytotoxicity of NK cells. The therapeutic
effectiveness of several promising humanized mAbs that are
reactive with tumor antigens (e.g., trastuzumab, rituximab,
cetuximab) may be improved further in combination with
IL-21. However, it is clear that human NK cells have dis-
tinct activation requirements with respect to IL-21 (17), and
the efficacy of any of these strategies using IL-21 will require
clinical assessment after IL-21 is deemed safe in early phase
trials in humans.
According to a previous report, the DC- -GalCer re-
sponse, as assessed by the number of IFN- –secreting iNKT
cells, was much stronger and prolonged than that obtained
with soluble  -GalCer (6). Our experiments confirmed that
the DC– -GalCer response also was associated with a supe-
rior protection against experimental tumor metastases. Nev-
ertheless, soluble and DC-pulsed  -GalCer displayed syner-
gistic activity when combined with delayed treatment with
systemic IL-21. The synergistic combination also seemed to
be effective in suppressing the initiation and growth of sub-
cutaneous tumors; however, it is now important to test fur-
ther the ability of DC/ GalCer/IL-21 combinations to sup-
press chemical- and oncogene-driven carcinogenesis as well
as established solid tumor deposits. Recently, it was shown
that activation of iNKT cells by  -GalCer rapidly activates
the maturation of DC, and thereby, acts as an adjuvant for T
cell immunity to a coadministered protein (43). It is now of
interest to evaluate the capacity of IL-21 to promote further
T cell immunity and memory to foreign- and self-antigens
in such a context.
MATERIALS AND METHODS
Mice. Inbred C57BL/6 and BALB/c WT mice were purchased from The
Walter and Eliza Hall Institute of Medical Research. The following
C57BL/6 gene-targeted mice were bred at the Peter MacCallum Cancer
Centre: C57BL/6 pfp-deficient (B6 pfp / ); C57BL/6 Fas ligand (FasL)
mutant (B6 gld); C57BL/6 RAG-1–deficient (B6 RAG-1 / ; from L.
Corcoran, The Walter and Eliza Hall Institute of Medical Research, Mel-
bourne, Australia); C57BL/6 IFN- –deficient (B6 IFN-  / ); B6 pfp /   
IFN-  /  (B6 pfp /  IFN-  / ); C57BL/6 IL-12–deficient (B6 IL-12 / ;
from Hoffmann-La Roche); C57BL/6 IL-18–deficient (B6 IL-18 / ; by
S. Akira, Osaka University, Japan); and B6 IL-12 /    IL-18 /  (B6 IL-
12 /  IL-18 / ). The following BALB/c gene-targeted mice were bred at
the Peter MacCallum Cancer Centre: BALB/c RAG-1 / ; BALB/c IFN-
  / ; BALB/c pfp / ; BALB/c pfp IFN-  / ; BALB/c TNF-related
apoptosis-inducing ligand (TRAIL)-deficient (TRAIL /  ; from J. Peschon,
AMGEN; reference 44); and BALB/c pfp TRAIL /  mice. All mice origi-
nally generated on a 129 background have been backcrossed between 10–
12 times onto the C57BL/6 or BALB/c background. Mice of 6–14 wk of
age were used in all experiments that were performed according to Animal
Experimental Ethics Committee Guidelines.
Isolation of spleen NK cells and cytotoxicity assay. NK cells were
prepared from the spleen of B6 WT or gene-targeted mice as described pre-
viously (45). The cytolytic activity of NK cells from various vehicle/ -Gal-
Cer– and pORF/pIL-21–treated mice was tested against Yac-1 target cells
by a standard 6-h 51Cr release assay as described previously (46).
Flow cytometric analysis. Mononuclear cells from the spleen, liver, and
thymus were isolated as described. For staining NK cells, mononuclear cells
were preincubated with CD16/32 (2.4G2) mAb to avoid the nonspecific
binding of antibodies to Fc R. Then the cells were incubated with a satu-
rating amount of PE-Cy5.5–conjugated TCR  mAb, APC–NK1.1 mAb,
and FITC-CD69 mAb or FITC-CD11b/Mac-1 mAb or PE-NKG2D
mAb. To analyze intracellular levels of NK cell IFN- , spleen cells were
harvested and incubated for 2 h in vitro with Golgistop (BD Bioscience).
The cells were incubated with a saturating amount of PE-Cy5.5–conju-
gated TCR  mAb and PE-conjugated NK1.1 mAb. An APC-conjugatedJEM VOL. 201, June 20, 2005 1983
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IFN-  mAb or isotype-matched control mAb was used after the cells were
fixed and permeabilized with Cytofix/perm Buffer (BD Biosciences). For
internal controls, mice were injected with poly I:C (200  g, Sigma-
Aldrich) and spleen cells were harvested 3 h later and subjected to intracel-
lular IFN-  staining. Flow cytometric analysis was performed with a LSR
instrument using FCS Express software.
Western analysis. Western blotting was performed essentially as described
(47). Spleen cells (107) were harvested from vehicle/pORF-, vehicle/pIL-
21–,  -GalCer/pORF–, and  -GalCer/pIL-21–treated mice 3 d after the
pORF/pIL-21 injection (day 6; Fig. 2 A). The cells were washed twice
with PBS and lysed on ice for 30 min in NP-40 lysis buffer (0.5% NP-40, 5
mM MgCl2, 25 mM KCL, 10 mM TrisHCL, pH 8.0), containing complete
mini-protease inhibitor cocktail (Roche Molecular Biochemicals). Cell de-
bris was removed by centrifugation at 13,000 rpm for 5 min, and the super-
natant was retained. Equal amounts of protein (determined by means of a
Bradford reaction) were separated on 12.5% or 15% SDS-polyacrylamide
gels and electroblotted onto nitrocellulose transfer membranes. Immuno-
blots were probed with rat mAb PI-8 to mouse pfp or mouse mAb to hu-
man  -tubulin (Sigma-Aldrich), and visualized by enhanced chemilumines-
cence (Amersham Biosciences).
Tumor cell lines. The following standard experimental mouse tumor cell
lines were used in vitro and in vivo: Yac-1 lymphoma (NK cell sensitive);
B16F10 melanoma (pfp-sensitive, FasL- and TRAIL-insensitive, H-2b);
4T1 mammary carcinoma (pfp- and TRAIL-sensitive and FasL-insensitive,
H-2d), and Renca renal cell carcinoma (pfp- and TRAIL-sensitive and
FasL-insensitive, H-2d). The maintenance of all tumor cell lines and the
sensitivities of lung metastases to various cytotoxic molecules in vitro and in
vivo were described previously (11, 28).
Tumor models in vivo. B16F10 and Renca tumor cell lines were inocu-
lated i.v. and 4T1 was inoculated into the mammary gland at the dose indi-
cated in the figure legends. The  -GalCer/IL-21 treatment schedule was
evaluated for its ability to reduce the expected metastatic tumor burden. For
B16F10 and Renca experimental metastasis models, mice were injected i.v.
with tumor cells and killed 14 d later, the lungs removed, and surface me-
tastases counted with the aid of a dissecting microscope. In the 4T1 model,
female mice were inoculated into the mammary gland with 2.5   104 cells
on day 0; 8 d later the primary tumor ( 10 mm2) was resected surgically.
Mice were killed at 25 d and spontaneous metastasis was measured by har-
vesting lungs and livers as described (44). Clonogenic metastases were calcu-
lated on a per organ basis. In all metastasis models, the data were recorded as
the mean number of metastases   SE of the mean. Some groups of treated
and control mice were monitored for survival and data are recorded as the
mean survival time (d)   SE of the mean. Mice were killed at the first signs
of labored breathing or loss of weight and ruffled fur, and lung tumor was
confirmed by autopsy. Significance was determined by a Kruskal-Wallis test.
Sarcomas were induced in male mice by 400  g MCA in 0.1 ml maize oil in
various  -GalCer/IL-21–treated C57BL/6 mice as described previously (27).
Palpable sarcomas ( 15 mm2) were recorded and tumor-free mice were
monitored for 250 d.
Cytokine/ -GalCer treatment protocols. Recombinant mouse IL-12
and IL-2 was provided by Genetics Institute and Chiron Corp., respec-
tively. Recombinant mouse IL-21 was provided by Zymogenetics. The
preparations of IL-2, IL-12, or IL-21 were diluted in PBS immediately be-
fore use.  -GalCer, a marine sponge glycolipid that activates CD1d-
restricted NKT cells was provided by the Pharmaceutical Research Labora-
tories, Kirin Brewery, and prepared as described (11).  -GalCer and the
control vehicle were resuspended in saline supplemented with 0.5%
polysorbate-20 (wt/vol). Some groups of mice were treated with one or
more of: (a)  -GalCer (1  g i.p.) or vehicle (200  l i.p.) and (b) IL-2
(100,000 I.U. i.p.), IL-12 (500 ng i.p.), or IL-21 (50  g i.p.), as indicated.
For hydrodynamic gene transfer, the expression pIL-21 pORF and the con-
trol vector pORF (provided by P. Hwu, National Cancer Institute, Be-
thesda, MD) were injected i.v. into mice as described previously (22). In
brief, mice were injected with 20  g of plasmid in a volume of 2 ml of sa-
line over a 5- to 7-s period. The volume of saline was based on the age and
weight of the mouse and did not exceed 10% of body weight.
Isolation of bone marrow–derived DCs. In some  -GalCer therapy
experiments,  -GalCer was administered pulsed on DCs. Bone marrow–
derived DCs were isolated from WT or gene-targeted mice and cultured in
10 ng/ml recombinant mouse GM-CSF and 5 ng/ml recombinant mouse
IL-4 (R&D Systems) as described (6, 48). From days 6 to 8 of culture, DCs
were supplemented with fresh media and additives, including 100 ng/ml
 -GalCer ( ) or vehicle ( ). 500,000 pulsed DCs were injected i.v. per
mouse on days 4 or 8 after tumor inoculation
NK cell depletion. NK cells, but not iNKT cells, were depleted specifi-
cally in B6 and BALB/c mice using 100  g i.p. rabbit anti-asialo GM1 anti-
body (Wako Chemicals) on days 0, 1, and 7 (after tumor inoculation) as de-
scribed (49, 50).
Statistical analysis. Significant differences in metastases were determined
by the Kruskal Wallis test. P   0.05 were considered significant.
Online supplemental material. Fig. S1 shows the suppression of subcu-
taneous tumor growth by  -GalCer/IL-21 combination. Online supple-
mental material is available at http://www.jem.org/cgi/content/full/jem.
20042280/DC1.
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